Exploring the risk for severe hypoglycemia in the pool of studied patients with T1D

Objective¹

This meta-analysis explores the risk for severe hypoglycemia with Gla-300 versus Gla-100 in the pool of studied patients with T1D.

Study Design

The following patients with T1D were pooled in the present study:

• Edition 4 (n=549): adult patients (age ≥18 years), worldwide²

• Edition JP 1 (n=243): adult patients (age ≥18 years), Japan³

• Edition Junior (n=463): children and adolescents (age 6−17 years), worldwide⁴

Previous Basal Insulin⁴

Results¹

Gla-300 provides effective and similar glycemic control versus Gla-100 in patients with T1D -0.3% HbA1c reduction LSM difference at week 26 (95% CI): 0.05% (-0.044 to 0.150)

Significant Lower percentage of patients with ≥1 Severe Hypoglycemic event with Gla-300 vs. Gla-100 from baseline to month 6 in pooled analysis -35% From baseline to month 6: OR (95% CI): 0.65 (0.42 to 0.98)

Conclusion¹

• Gla-300 showed a lower risk for severe hypoglycemia compared with Gla-100 in a broad spectrum of patients with T1D, especially during the titration phase.
• Gla-300 provides effective and similar glycemic control versus Gla-100 in patients with T1D.

Gla-300, insulin glargine 300 U/ml; Gla-100, insulin glargine 100U/ml; T1D, type 1 diabetes; IDet, insulin detemir; NPH, Neutral Protamine Hagedorn insulin; IDeg, insulin degludec; CI, confidence interval; LS, least square; SE, standard error